Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1602748 | 0.84 | NFKB1 (0.46) | ALDH1A1KDM4ESMN1; SMN2NPC1MAPT | |
| SCHEMBL30110408 | 0.84 | NFKB1 (0.46) | ALDH1A1KDM4ESMN1; SMN2NPC1MAPT | |
| SCHEMBL427402 | 0.83 | ALDH1A1 (0.63) | ALDH1A1KDM4ESMN1; SMN2NPC1MAPT | |
| SCHEMBL19134228 | 0.82 | TSHR (0.46) | ALDH1A1KDM4EMAPTTSHRCFTR | |
| SCHEMBL8590367 | 0.81 | RAB9A (0.47) | ALDH1A1KDM4ESMN1; SMN2NPC1MAPT | |
| SCHEMBL22120120 | 0.80 | ATM (0.41) | ALDH1A1KDM4ENFKB1NFKB2RELA | |
| SCHEMBL12123836 | 0.79 | POLB (0.46) | ALDH1A1KDM4ESMN1; SMN2NPC1MAPT | |
| SCHEMBL10585289 | 0.79 | ALDH1A1 (0.38) | ALDH1A1KDM4ESMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL4274478 | 0.79 | HPGD (0.44) | ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL3055707 | 0.79 | NPSR1 (0.39) | ALDH1A1KDM4ESMN1; SMN2NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114044774-B | EGFR inhibitor and preparation method and application thereof | 光武惠文生物科技(北京)有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-114044774-A | EGFR inhibitor and preparation method and application thereof | 北京超维知药科技有限公司 | 2022-02-15 | — | — | CN | disclosed |
| EP-2914580-B1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEMICAL LTD (KR) | 2019-02-20 | — | — | EP | disclosed |
| US-9447044-B2 | Thioaryl derivatives as GPR120 agonists | LG LIFE SCIENCES LTD. (KR) | 2016-09-20 | — | — | US | disclosed |
| US-20150291527-A1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2015-10-15 | — | — | US | disclosed |
| EP-2914580-A1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | LG Life Sciences Ltd. (KR) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014069963-A1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2014-05-08 | — | — | WO | disclosed |
| CN-102066335-A | Substituted pyrimidin-5-carboxamides 281 | ASTRAZENECA AB | 2011-05-18 | — | — | CN | disclosed |
| EP-2271629-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | ALDH1A1 53/4885KDM4E 1727/4885SMN1; SMN2 2203/4885 |
| US-20150291527-A1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | GPR119, GLP1R, GCGR | ALDH1A1 1822/4885KDM4E 2840/4885SMN1; SMN2 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.